GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (OTCPK:NNCSF) » Definitions » Risk Assessment

Nanosonics (Nanosonics) Risk Assessment


View and export this data going back to 2010. Start your Free Trial

What is Nanosonics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Nanosonics is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Nanosonics's Risk Assessment

For the Medical Instruments & Supplies subindustry, Nanosonics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanosonics's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Nanosonics's Risk Assessment falls into.


Nanosonics  (OTCPK:NNCSF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Nanosonics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Nanosonics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanosonics (Nanosonics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanosonics Ltd (OTCPK:NNCSF) » Definitions » Risk Assessment
Comparable Companies
ASX:TRJ ASX:SDI ASX:AHC ASX:OSX ASX:ANN ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD OCSE:COLO B TSE:4543 WST XSWX:STMN XPAR:DIM TSE:7733 COO BAX HOLX
Traded in Other Exchanges
OQS:Germany NAN:Australia
Address
7-11 Talavera Road, Level 1 Building A, Macquarie Park, Sydney, NSW, AUS, 2113
Website
https://www.nanosonics.com.au
Nanosonics is a single-product firm and its trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low temperature sonically activated hydrogen peroxide mist that is suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection across patients. Nanosonics' revenue is made up of capital sales of trophon units, ongoing consumables sales, and service revenue. At June 2022, there were 29,850 trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, roughly 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in Asia-Pacific.